Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials

被引：0

作者：

Su, Ching-Hui ^{[1
]}

Chang, Ying-Tzu ^{[1
]}

Tseng, Huan-Shu ^{[1
]}

Kuo, Chan-Yen ^{[2
]}

Chen, Jin-Hua ^{[3
,4
]}

Chiena, Po-Yu ^{[3
]}

Changf, Yao-Jen ^{[6
,7
]}

Hung, Chin-Chuan ^{[1
,5
,8
]}

机构：

[1] China Med Univ, Coll Pharm, Dept Pharm, Taichung 406040, Taiwan

[2] Tzu Chi Univ, Inst Oral Med & Mat, Coll Med, Hualien 97004, Taiwan

[3] Taipei Med Univ, Grad Inst Data Sci, Coll Management, Taipei 11031, Taiwan

[4] Taipei Med Univ, Hlth Data Analyt & Stat Ctr, Off Data Sci, Taipei 11031, Taiwan

[5] China Med Univ Hosp, Dept Pharm, Taichung 404327, Taiwan

[6] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Surg, New Taipei City 23142, Taiwan

[7] Buddhist Tzu Chi Univ, Sch Med, Dept Surg, Hualien 97004, Taiwan

[8] Asia Univ, Dept Healthcare Adm, Taichung 41354, Taiwan

来源：

CLINICAL MEDICINE | 2025年 / 25卷 / 04期

关键词：

Alzheimer's disease; Immunotherapy; Anti-amyloid beta; Anti-tau proteins; Network meta-analysis; RATING-SCALE; ABSENCE; BOXES; SUM;

D O I：

10.1016/j.clinme.2025.100336

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Alzheimer's disease (AD) remains a major challenge due to limited effective therapies. Moreover, direct comparisons between newly developed and symptomatic drugs are lacking. This network meta-analysis aimed to compare the efficacy and safety of immunotherapies for AD. Methods: A systematic search of PubMed, Embase, the Cochrane Library and ClinicalTrials.gov was conducted for randomised controlled trials (RCTs) up to 29 June 2024. Eligible studies included adults with AD receiving immunotherapy versus placebo or symptomatic treatment. Results: Fifty-nine RCTs were included. Donanemab and lecanemab ranked among the most effective treatments for improving cognitive function (Clinical Dementia Rating Scale-Sum of Boxes P-scores: 0.88 and 0.77) and daily activities (Alzheimer's Disease Cooperative Study-Activities of Daily Living P-scores: 0.85 and 0.90), based on network meta-analysis findings. Conclusions: Anti-A /3 monoclonal antibodies, particularly donanemab and lecanemab, demonstrated superior efficacy over other immunotherapies in slowing cognitive deterioration, supporting their role in AD management. PROSPERO registration number: CRD42023461680.

引用

页数：7

共 43 条

[1] 2023 Alzheimer's disease facts and figures [J].

不详 .

ALZHEIMERS & DEMENTIA, 2023, 19 (04) :1598-1695

[2]

[Anonymous], 2023, FDA Converts Novel Alzheimers Disease Treatment to Traditional Approval

[3]

[Anonymous], 2021, FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors

[4]

[Anonymous], 2023, Dementia

[5] Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β [J].

Arndt, Joseph W. ;

Qian, Fang ;

Smith, Benjamin A. ;

Quan, Chao ;

Kilambi, Krishna Praneeth ;

Bush, Martin W. ;

Walz, Thomas ;

Pepinsky, R. Blake ;

Bussiere, Thierry ;

Hamann, Stefan ;

Cameron, Thomas O. ;

Weinreb, Paul H. .

SCIENTIFIC REPORTS, 2018, 8

[6] Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease [J].

Ayalon, Gai ;

Lee, Seung-Hye ;

Adolfsson, Oskar ;

Foo-Atkins, Corinne ;

Atwal, Jasvinder K. ;

Blendstrup, Mira ;

Booler, Helen ;

Bravo, Joseph ;

Brendza, Robert ;

Brunstein, Flavia ;

Chan, Ruby ;

Chandra, Priya ;

Couch, Jessica A. ;

Datwani, Akash ;

Demeule, Barthelemy ;

DiCara, Danielle ;

Erickson, Rich ;

Ernst, James A. ;

Foreman, Oded ;

He, Dongping ;

Hotzel, Isidro ;

Keeley, Michael ;

Kwok, Michael C. M. ;

Lafrance-Vanasse, Julien ;

Lin, Han ;

Lu, Yanmei ;

Luk, Wilman ;

Manser, Paul ;

Muhs, Andreas ;

Ngu, Hai ;

Pfeifer, Andrea ;

Pihlgren, Maria ;

Rao, Gautham K. ;

Scearce-Levie, Kimberly ;

Schauer, Stephen P. ;

Smith, William B. ;

Solanoy, Hilda ;

Teng, Edmond ;

Wildsmith, Kristin R. ;

Yadav, Daniela Bumbaca ;

Ying, Yong ;

Fuji, Reina N. ;

Kerchner, Geoffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (593)

[7] MR Imaging Features of Amyloid-Related Imaging Abnormalities [J].

Barakos, J. ;

Sperling, R. ;

Salloway, S. ;

Jack, C. ;

Gass, A. ;

Fiebach, J. B. ;

Tampieri, D. ;

Melancon, D. ;

Miaux, Y. ;

Rippon, G. ;

Black, R. ;

Lu, Y. ;

Brashear, H. R. ;

Arrighi, H. M. ;

Morris, K. A. ;

Grundman, M. .

AMERICAN JOURNAL OF NEURORADIOLOGY, 2013, 34 (10) :1958-1965

[8] Longitudinal Sensitivity of Alzheimer's Disease Severity Staging [J].

Benoit, Julia S. ;

Chan, Wenyaw ;

Piller, Linda ;

Doody, Rachelle .

AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2020, 35

[9] Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials [J].

Coley, Nicola ;

Andrieu, Sandrine ;

Jaros, Mark ;

Weiner, Michael ;

Cedarbaum, Jesse ;

Vellas, Bruno .

ALZHEIMERS & DEMENTIA, 2011, 7 (06) :602-610

[10] Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease [J].

Cummings, Jeffrey ;

Osse, Amanda M. Leisgang ;

Cammann, Davis ;

Powell, Jayde ;

Chen, Jingchun .

BIODRUGS, 2024, 38 (01) :5-22

← 1 2 3 4 5 →